{"id":"W3202447968","doi":"10.1016/j.annonc.2021.08.1089","title":"576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"Advanced Accelerator Applications; Astellas Pharma; Peter MacCallum Cancer Centre; Clovis Oncology; Endocyte; Sanofi; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Taxane; Quality of life (healthcare); Glutamate carboxypeptidase II; Progression-free survival; Brief Pain Inventory; Randomized controlled trial; Cancer; Chemotherapy; Physical therapy; Breast cancer; Chronic pain","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001646826,0.0008532786,0.001721595,0.0002695131,0.0003372856,0.0009803392,0.0005555448,0.0008389605,0.001731231],"category_scores_gemma":[0.0006198629,0.0004315414,0.001673724,0.0003738432,0.0007473864,0.0005702651,0.0003484903,0.002020622,0.0003863692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007891238,"about_ca_system_score_gemma":0.001246283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002060398,"about_ca_topic_score_gemma":0.003233505,"domain_scores_codex":[0.9994522,0.0002872288,0.00001788772,0.0000530117,0.00006560708,0.0001240452],"domain_scores_gemma":[0.9996282,0.00007017677,0.00008878606,0.00002955802,0.00003054735,0.0001527685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8475631,0.03706144,0.04285045,0.0005518101,0.003345435,0.0001169763,0.000227617,0.002212377,0.01522411,0.0002687002,0.001753021,0.04882484],"study_design_scores_gemma":[0.396708,0.4721946,0.1203612,0.00003591742,0.002262393,0.000178205,0.0001564235,0.002589975,0.003368023,0.0002064974,0.001877884,0.00006090335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982091,0.0006936996,0.00008028265,0.00009513574,0.00003295211,0.0001890737,0.000193747,0.00001071039,0.0004952818],"genre_scores_gemma":[0.9972302,0.0005014768,0.0002413229,0.0002661845,0.00006849085,0.0002893909,0.0005832,0.000008324873,0.0008113855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002060398,"threshold_uncertainty_score":0.008709371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1217485326737848,"score_gpt":0.4792702461281007,"score_spread":0.3575217134543159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}